Let's Play PET References - "B"

[Back to Menu] [Back to Index]
  • Bacharach, S, Douglas, M, Carson, R, Kalkowski, P, Freedman, N, Perrone-Filardi, P, Bonow, R: Three-dimensional registration of cardiac positron emission tomography attenuation scans. J Nucl Med, 34:311-321, 1993.

  • Bahn M, Huang S, Hawkins R, Satyamurthy N, Hoffman J, et al. Models for in vivo kinetic interactions of dopamine D2-neuroreceptors and 3-(2'-[18F]fluoroethyl)spiperone examined with positron emission tomography. J Cereb Blood Flow Metab, 9:840-9, 1989.

  • Bailet, JW, Abemayor, E, Jabour, BA, Hawkins, RA, Hoh, CK, Ward, PH. Positron emission tomography: A new precise modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope, 102:281-288, 1992.

  • Bakir MA; Eccles SA; Babich JW; Aftab N; Styles JM; Dean CJ; Ott RJ. c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med, 1992, 33:2154-60.

  • Baron J. Depression of energy metabolism in distant brain structures: studies with positron emission tomography in stroke patients. Sem Neurol, 9:281-5, 1989.

  • Barrio J. Approaches to the design of biochemical probes for positron emission tomography. Neurochem Res, 16:1047-54, 1991.

  • Barrio J, Huang S, Melega W, Yu D, Hoffman J, Schneider J, et al. 6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures. J Neurosci Res, 27:487-93, 1990.

  • Barrio J, Satyamurthy N, Huang S, Keen R, Nissenson C, et al. 3-(2'-[18F] fluoroethyl) spiperone: in vivo biochemical and kinetic characterization in rodents, nonhuman primates, and humans. J Cereb Blood Flow Metab, 9:830-9, 1989.

  • Bauer R; Bergmann R; Beyer GJ; Manfrass P; Steinbach J; Kretzschmar M; Enghardt W; Hoyer D; Gunther K; Schubert H. Investigations of cerebral glucose utilization into the newborn brain: a [18F]-FDG positron emission tomography study using a high resolution multiwire proportional chamber detector device. Exp Pathol, 1991, 42:229-33.

  • Baumgartner, F, Barrio, J, Henze, E, Schelbert, H, MacDonald, N, Phelps, M, et al.: [13N] Labeled L-Amino Acids for in vivo Quantitative Assessment of Local Myocardial Metabolism. J Med Chem, 24:764-766, 1981.

  • Baxter, L Jr, Mazziotta, J, Pahl, J, Grafton, S, et al: Psychiatric, genetic, and positron emission tomographic evaluation of persons at risk for Huntington's disease. Arch Gen Psychiat, 49:148-54, 1992.

  • Beaney, R. Positron emission tomography in the study of human tumors. Sem Nucl Med, 14:324-341, 1984.

  • Bellina C; Parodi O; Camici P; Salvadori P; Taddei L; Fusani L; Guzzardi R; Klassen G; L'Abbate A; Donato L. Simultaneous in vitro and in vivo validation of nitrogen-13-ammonia for the assessment of regional myocardial blood flow. J Nucl Med, 1990, 31:1335-43.

  • Benson, D, Kuhl, D, Hawkins, R, Phelps, M, et al., The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol 40:711-14, 1983.

  • Bergmann S. Clinical applications of assessments of myocardial substrate utilization with positron emission tomography. Molec Cell Biochem, 1989, 88:201-9.

  • Bergmann S; Herrero P; Markham J; Weinheimer C; Walsh M. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Amer Coll Cardiol, 1989, 14:639-52.

  • Bergstrom, M. Positron emission tomography in tumor diagnosis and treatment follow-up. Acta Oncologica, 32: 183-188, 1993.

  • Bernardi, S, Trimble, M, Frackowiak, R, Wise, R, Jones, T. An interictal study of partial epilepsy using positron emission tomography and the oxygen-15 inhalation technique. J Neurol Neurosurg Psychiatr, 46:473-7, 1983.

  • Berridge, M, Cassidy, E, Terris, A: A routine, automated synthesis of oxygen-15-labeled butanol for positron tomography. J Nucl Med, 31:1727-31, 1990.

  • Berry, J, Hoffman, J, Steenbergen, C, Baker, J, Floyd, C, Van Trigt, P, Hanson, M, Coleman, R: Human pathologic correlation with PET in ischemic and nonischemic cardiomyopathy. J Nucl Med, 34:39-47, 1993.

  • Bettinardi, V, Gilardi, MC, Lucignani, G, et al: A procedure for patient repositioning for misalignment between transmission and emission data in PET heart studies. J. Nucl. Med., 34:137-142, 1993.

  • Bhatt, M, Snow, B, Martin, W, et al: Positron emission tomography suggests that the rate of progression of idiopathic Parkinsonism is slow. Ann Neurol, 29:673-7, 1991.

  • Bjšrklund, A: Neural transplantationĐan experimental tool with clinical possibilities. Trends Neurosci, 14:319-22, 1991.

  • Blau, M, Ganatra, R, Bender, M. 18F-Fluoride for bone imaging. Semin Nucl Med, 2:31-37, 1972.

  • Blin, J, Baron, J, Dubois, B, Crouzel, C, Fiorelli, M, Attarlevy, D, Pillon, B, Fournier, D, Vidailhet, M, Agid, Y. Loss of brain 5-HT(2) receptors in Alzheimer's disease - invivo assessment with positron emission tomography and [F-18]setoperone. Brain, 116: 497-510, 1993.

  • Bol A; Melin J; Vanoverschelde J; Baudhuin T; Vogelaers D; De Pauw M; Michel C; Luxen A; Labar D; Cogneau M; et al. Direct comparison of [13N]ammonia and [15O]water estimates of perfusion with quantification of regional myocardial blood flow by microspheres. Circulation, 1993, 87:512-25.

  • Boles-Ponto, L, Ponto, J: Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Parts I & II). Clin Pharmokinet 22:211-22, 274-83, 1992.

  • Borbely, K, Fulham, MJ, Brooks, RA, Di Chiro, G: PET-fluorodeoxyglucose of cranial and spinal neuromas. J Nucl Med, 33:1931-1934, 1992.

  • Brooks, D: Detection of preclinical Parkinson's disease with PET. Neurology, 41(Suppl 2):24-7, 1991.

  • Brown, M, Marshall, D, Sobel, B, Bergmann, S: Delineation of myocardial oxygen utilization with carbon-11-labeled acetate. Circulation, 76:687-96, 1987.

  • Brown M; Myears D; Bergmann S. Validity of estimates of myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography despite altered patterns of substrate utilization. J Nucl Med, 1989, 30:187-93.

  • Brun, A, Englund, E. The pattern of degeneration in Alzheimer's disease: Neuronal loss and histopathological grading. Histopathology, 5:549-564, 1981.

  • Brunken, R and Schelbert, H: Positron emission tomography in clinical cardiology. Cardiol Clin , 7:607-29, 1989.

  • Burn D; Brooks D. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology, 43:552-6, 1993.

  • Burn, D, Mark, M, Playford, E, Maraganore, D, Zimmerman, T, Duvoisin, R, Harding, A, Marsden, C, Brooks, D: Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology, 42:1894-1900, 1992.

  • Burns, H, Dannals, R, Langstrom, B, Ravert, H, et al: (3-N-[11C] methyl) spiperone, a ligand binding to dopamine receptors: Radiochemical synthesis and biodistribution studies in mice. J Nucl Med, 25:1222-7, 1984.

  • Burns, H, Gibson, R, Dannals, R, Siegl, P (Eds): Nuclear Imaging in Drug Discovery, Development, and Approval. BirkhŠuser, Boston, 1993.

  • Burns, H, Lever, J, Dannals, R, Frost, J, et al: Synthesis of ligands for imaging opiate receptors by positron emission tomography: Carbon-11 labeled diprenorphine. J Label Compd Radiopharm, 21:1167-9, 1984.

  • Buxton, D, Nienaber, C, Luxen, A, Ratib, O, Hansen, H, Phelps, M, Schelbert, H. Noninvasive quantitation of regional myocardial oxygen consumption in vivo with [11C]acetate and dynamic positron emission. Circulation, 79:134-42, 1989.

  • Buxton D; Schelbert H. Measurement of regional glucose metabolic rates in reperfused myocardium. Am J Physiol, 1991, 261:H2058-68.

    Let's Play PET, Copyright 1992, 1993 Regents of the University of California
    All Rights Reserved

    [Back to Menu] [Back to Index]